Rocket Pharma gets FDA nod for first pediatric gene therapy targeting severe LAD-I
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
Subscribe To Our Newsletter & Stay Updated